Bioxodes atteint un premier objectif de recrutement pour l'essai de phase 2a sur l'hémorragie intracérébrale
19. Dezember 2024 02:30 ET
|
Bioxodes
Bioxodes a recruté les 16 premiers patients pour l'essai de BIOX-101Une analyse intermédiaire sera réalisée à la fin du traitement de la première cohorte de patientsBIOX-101 est un candidat...
Bioxodes meets enrollment milestone in Phase 2a intracerebral hemorrhagic stroke trial
19. Dezember 2024 02:30 ET
|
Bioxodes
Bioxodes has enrolled first 16 patients in trial with BIOX-101Completing treatment of first cohort of patients will trigger interim analysisBIOX-101 is a first-in-class drug candidate, a peptide...
RapidPulse Receives FDA Approval to Begin IDE Study in Ischemic Stroke Using Innovative Cyclic Aspiration System – Recently Completed Clinical Trial Shows Significantly Higher First Pass and Frontline Success Rates
11. Dezember 2024 10:30 ET
|
RapidPulse, Inc
MIAMI, Dec. 11, 2024 (GLOBE NEWSWIRE) -- RapidPulse, Inc., a Delaware corporation headquartered in Miami, Florida focused on improving the treatment success rate for acute ischemic stroke (AIS)...
Route 92 Medical Gains EU and MDSAP Certification for its Neurovascular Stroke-Intervention-Focused Product Portfolio
20. November 2024 08:00 ET
|
Route 92 Medical, Inc.
Route 92 Medical announces EU and MDSAP certification for its neurovascular stroke-intervention-focused product portfolio.
ZyVersa Therapeutics Announces Peer-Reviewed Publication Demonstrating That Inflammasome ASC Inhibitor IC 100 Protects Against Stroke-Related Cardiovascular Injury and Dysfunction in Preclinical Trial
20. November 2024 07:55 ET
|
ZyVersa Therapeutics
Stroke-related cardiovascular injury and dysfunction are induced by AIM2 inflammasome activation in the heart, which can be blocked by ZyVersa's IC 100.
Route 92 Medical Announces $50 Million Series F Extension Equity Financing
23. September 2024 09:00 ET
|
Route 92 Medical, Inc.
Route 92 Medical announces $50 million series F extension equity financing to support its commercial expansion.
Pharmazz Inc. announces that Dr. Neil Marwah has joined the Company as its President
11. September 2024 07:00 ET
|
Pharmazz, Inc.
Pharmazz Inc. announces that Dr. Neil Marwah has joined the Company as its President.
Pharmazz Inc. and Sun Pharma entered into an agreement under which Sun Pharma will invest up to $15 Million in Pharmazz, Inc.
21. August 2024 07:00 ET
|
Pharmazz, Inc.
Pharmazz Inc. and Sun Pharma entered into an agreement under which Sun Pharma will invest up to $15 Million in Pharmazz, Inc.
Bioxodes annonce la recommandation positive du DMC pour son essai de phase 2a dans le traitement des AVC hémorragiques avec BIOX-101
21. August 2024 02:30 ET
|
Bioxodes
Le Comité de surveillance des données (DMC, Data Monitoring Committee) a recommandé la poursuite de l’étude après l’examen planifié des données provenant des 8 premiers patients L’analyse des...
Bioxodes reports positive DMC meeting for BIOX-101 Phase 2a trial in intracerebral hemorrhagic stroke
21. August 2024 02:30 ET
|
Bioxodes
Planned Data Monitoring Committee (DMC) meeting recommended continuation of the study after reviewing data from the first 8 patients Interim data from 16 patients scheduled around the end of 2024 ...